Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $5.4350 (-0.46%) ($5.4350 - $5.4350) on Mon. Dec. 27, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.05% (three month average) | RSI | 44 | Latest Price | $5.4350(-0.46%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.2% a day on average for past five trading days. | Weekly Trend | AUTL declines -9.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(65%) IBB(60%) IBUY(58%) ARKG(56%) ARKK(55%) | Factors Impacting AUTL price | AUTL will decline at least -2.525% in a week (0% probabilities). VIXM(-40%) VXX(-32%) TLT(-24%) SHY(-22%) TIP(-19%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.525% (StdDev 5.05%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-9.78(-279.94%) | Resistance Level | $5.9 | 5 Day Moving Average | $5.37(1.21%) | 10 Day Moving Average | $5.5(-1.18%) | 20 Day Moving Average | $5.9(-7.88%) | To recent high | -24.1% | To recent low | 4.4% | Market Cap | $284m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |